 |
As Viralytics proceeds with clinical trails, general information and web-links regarding currently active trials will be presented |
Clinical trials are currently being run to investigate the use of CAVATAK™ in humans to help treat: advanced melanoma, breast and prostate cancers.
ACTIVE CLINICAL TRIALS:
| Phase 2 | Phase 1 |
|
Stage IIIc & Stage IV Malignant Melanoma - Intratumoural CAVATAK™ Monotherapy Study |
Melanoma, Breast and Prostate Intravenous Trial Recruiting patients in Australia
|
A Phase II Melanoma Clinical Trial: The CALM Study
A phase II Trial to investigate the use of CAVATAK™ for treatment of Late Stage Melanoma has been initiated. Patient recruitment has commenced and is ongoing at multiple sites. Additional site selection is underway in the USA under FDA regulatory conditions. Viralytics received approval from the FDA to run this trial in the USA in June 2011.
For further information about this trial please visit the Clinical Trial website using the following link:
ClinicalTrials.gov Identifier: NCT01227551
Status: Recruiting patients.
Phase I Melanoma, Breast and Prostate Trial:
Melanoma, Breast and Prostate cancer patients are needed for the completion of our intravenous CAVATAK™ trial. Patients with stage IV solid tumor disease who are over 18 years of age and who have failed or refused standard treatment may be suitable for inclusion in the trial.
For further information about this trial please visit the Clinical Trial website using the following link:
ClinicalTrials.gov Identifier: NCT00636558
Status: Recruiting patients.
Sites: Redcliff Hospital, Qld and St George Hospital, Kogarah, NSW
ABOUT CLINICAL TRIALS
Clinical Trials are conducted by medical practitioners as scientific research to investigate the trial drug as a future medicine.
PHASE I TRIALS: Initial studies to determine the safety, and the mode of actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness. These trials are conducted on volunteered subjects. Volunteers may include healthy participants and/or patients.
PHASE II TRIALS: These are clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.
PHASE III TRIALS: Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling.
PARTICIPATION IN A TRIAL
Please see further links or contact us (clinicaltrials@viralytics.com) for further information on CAVATAK™ trials.
